Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy

Theodore S. Hong, Clemens Grassberger, Beow Y. Yeap, Wenqing Jiang, Jennifer Y. Wo, Lipika Goyal, Jeffrey W. Clark, Christopher H. Crane, Eugene J. Koay, Simona Dima, Christine E. Eyler, Irinel Popescu, Thomas F. DeLaney, Andrew X. Zhu, Dan G. Duda

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Radiotherapy shows excellent local control in liver cancers but carries the risk of radiation-induced liver dysfunction and liver failure. We conducted a study of plasma hepatocyte growth factor (HGF) in a clinical trial of proton radiotherapy in patients with unresectable liver cancers (NCT00976898), and in an observational study for liver cancer patients undergoing surgical treatments. Liver dysfunction within 3 months after radiotherapy—a Childs−Turcotte−Pugh (CTP) score increase of 1 point or more—occurred in 9/34 (26%) of patients. Patients with no increase in CTP score had lower pretreatment plasma HGF level (p = 0.015). Both the increase in CTP score (p = 0.034) and the pretreatment plasma HGF (p = 0.017) were associated with OS. Plasma HGF was significantly associated with presence of cirrhosis (p = 0.0027) and with Model for End-stage Liver Disease (MELD) score (p < 0.0001), but not with OS in surgical liver cancer patients. Pretreatment plasma HGF is a candidate biomarker for patient selection for radiotherapy.

Original languageEnglish (US)
Article number22
Journalnpj Precision Oncology
Volume2
Issue number1
DOIs
StatePublished - Dec 1 2018

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy'. Together they form a unique fingerprint.

Cite this